XML 66 R42.htm IDEA: XBRL DOCUMENT v3.20.1
Segments (Tables)
 3 Months Ended
Mar. 31, 2020
Segment Reporting [Abstract]  
Information by Reportable Segment
Information by reportable segment was as follows:
 
Three Months Ended March 31, 2020
 
PGEN Therapeutics
 
ActoBio
 
MBP Titan
 
Trans Ova
 
Human Biotherapeutics
 
All Other
 
Total
Revenues from external customers
$
160

 
$
198

 
$
—

 
$
16,785

 
$
10,363

 
$
2,292

 
$
29,798

Intersegment revenues
2,103

 
—

 
7

 
109

 
—

 
281

 
2,500

Total segment revenues
$
2,263

 
$
198

 
$
7

 
$
16,894

 
$
10,363

 
$
2,573

 
$
32,298

 
 
 
 
 
 
 
 
 
 
 
 
 
 
Segment Adjusted EBITDA
$
(6,919
)
 
$
(1,990
)
 
$
(8,764
)
 
$
(1,199
)
 
$
(1,338
)
 
$
492

 
$
(19,718
)
 
Three Months Ended March 31, 2019
 
PGEN Therapeutics
 
ActoBio
 
MBP Titan
 
Trans Ova
 
Human Biotherapeutics
 
All Other
 
Total
Revenues from external customers
$
1,181

 
$
401

 
$
1,481

 
$
14,934

 
$
383

 
$
4,097

 
$
22,477

Intersegment revenues
2,365

 
443

 
—

 
273

 
—

 
13

 
3,094

Total segment revenues
$
3,546

 
$
844

 
$
1,481

 
$
15,207

 
$
383

 
$
4,110

 
$
25,571

 
 
 
 
 
 
 
 
 
 
 
 
 
 
Segment Adjusted EBITDA
$
(7,369
)
 
$
(2,438
)
 
$
(8,026
)
 
$
(2,226
)
 
$
(223
)
 
$
(1,238
)
 
$
(21,520
)
Reconciliation of Operating Profit (Loss) from Segments to Consolidated
The table below reconciles total segment revenues from reportable segments to total consolidated revenues:
 
Three Months Ended 
 March 31,
 
2020
 
2019
Total segment revenues from reportable segments
$
29,725

 
$
21,461

Other revenues, including from other operating segments
3,214

 
4,218

Elimination of intersegment revenues
(3,101
)
 
(3,094
)
Total consolidated revenues
$
29,838

 
$
22,585

The table below reconciles Segment Adjusted EBITDA for reportable segments to consolidated net loss from continuing operations before income taxes:
 
Three Months Ended 
 March 31,
 
2020
 
2019
Segment Adjusted EBITDA for reportable segments
$
(20,210
)
 
$
(20,282
)
All Other Segment Adjusted EBITDA
492

 
(1,238
)
Remove cash paid for capital expenditures and investments in affiliates
2,741

 
3,512

Add recognition of previously deferred revenue associated with upfront and milestone payments
12,473

 
4,612

Other expenses:
 
 
 
Interest expense
(4,592
)
 
(4,305
)
Depreciation and amortization
(4,810
)
 
(5,344
)
Stock-based compensation expense
(5,718
)
 
(8,248
)
Adjustment related to bonuses paid in equity awards
2,833

 
—

Equity in net loss of affiliates
(351
)
 
(748
)
Other
9

 
—

Unallocated corporate costs
(10,182
)
 
(18,022
)
Eliminations
(2,587
)
 
(2,850
)
Consolidated net loss from continuing operations before income taxes
$
(29,902
)
 
$
(52,913
)